Allarity Therapeutics Files 8-K
Ticker: ALLR · Form: 8-K · Filed: Aug 27, 2025 · CIK: 1860657
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
Allarity Therapeutics filed an 8-K, likely routine docs. No major news yet.
AI Summary
On August 26, 2025, Allarity Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial transactions or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates a routine update or submission of documents to the SEC, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without immediate disclosure of significant negative events.
Key Players & Entities
- Allarity Therapeutics, Inc. (company) — Registrant
- August 26, 2025 (date) — Date of earliest event reported
- 001-41160 (other) — Commission File Number
- DE (other) — State of incorporation
- 123 E Tarpon Ave, Tarpon Springs, FL 34689 (other) — Address of principal executive offices
- 401-426-4664 (other) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Allarity Therapeutics, Inc.?
The filing is a Current Report on Form 8-K, indicating "Other Events" and "Financial Statements and Exhibits" as the items being reported.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is August 26, 2025.
What is the Commission File Number for Allarity Therapeutics, Inc.?
The Commission File Number for Allarity Therapeutics, Inc. is 001-41160.
In which state was Allarity Therapeutics, Inc. incorporated?
Allarity Therapeutics, Inc. was incorporated in Delaware (DE).
What is the principal executive office address and phone number for Allarity Therapeutics, Inc.?
The principal executive office is located at 123 E Tarpon Ave, Tarpon Springs, FL 34689, and the telephone number is (401) 426-4664.
Filing Stats: 445 words · 2 min read · ~1 pages · Grade level 10.4 · Accepted 2025-08-27 08:00:43
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ALLR The Nasdaq Stock Mar
Filing Documents
- ea0254632-8k_allarity.htm (8-K) — 24KB
- ea025463201ex99-1_allarity.htm (EX-99.1) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-25-080923.txt ( ) — 209KB
- allr-20250826.xsd (EX-101.SCH) — 3KB
- allr-20250826_lab.xml (EX-101.LAB) — 33KB
- allr-20250826_pre.xml (EX-101.PRE) — 22KB
- ea0254632-8k_allarity_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On August 26, 2025, Allarity Therapeutics, Inc. (the "Company") announced in a press release that the U.S. Food and Drug Administration has granted Fast Track designation to stenoparib, the Company's investigational treatment for patients with advanced ovarian cancer. The Company's press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release, dated August 26, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Allarity Therapeutics, Inc. Date: August 27, 2025 By: /s/ Thomas H. Jensen Thomas H. Jensen Chief Executive Officer 2